VIDEO: Two studies highlight darolutamide results
Click Here to Manage Email Alerts
In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discussed two studies that highlight positive results from darolutamide for prostate cancer.
The ARAMIS trial found that darolutamide was "quite beneficial" for non-metastatic castration-resistant prostate cancer when used in addition with continuing androgen deprivation therapy, Shenderov said.
"Combine that with the ODENZA data that looked at the idea of darolutamide vs enzalutamide in a head-to-head comparison of adverse events... I think that's exciting," Shenderov said
Collapse
Gratzke CJ, et al. Abstract 630p. Presented at ESMO Congress 2021; Sept. 16-21, 2021 (virtual meeting).
Read more about
Click Here to Manage Email Alerts